FIGN

Summary

FIGN (fidgetin, microtubule severing factor, HGNC:13285) is a protein-coding gene on chromosome 2q24.3, encoding Fidgetin (Q5HY92). ATP-dependent microtubule severing protein.

Predicted to enable ATP hydrolysis activity and microtubule severing ATPase activity. Predicted to be involved in cell division and microtubule cytoskeleton organization. Predicted to act upstream of or within locomotory behavior. Predicted to be located in nuclear matrix.

Source: NCBI Gene 55137 — RefSeq curated summary.

At a glance

• GWAS associations: 61
• Clinical variants (ClinVar): 102 total
• MANE Select transcript: NM_018086

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13285
Approved symbol	FIGN
Name	fidgetin, microtubule severing factor
Location	2q24.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000182263
Ensembl biotype	protein_coding
OMIM	605295
Entrez	55137

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000333129, ENST00000409634, ENST00000482917, ENST00000879555

RefSeq mRNA: 2 — MANE Select: NM_018086 NM_001321825, NM_018086

CCDS: CCDS2221

Canonical transcript exons

ENST00000333129 — 3 exons

Exon	Start	End
ENSE00001379551	163735838	163736008
ENSE00001944382	163602611	163611806
ENSE00003363773	163734903	163735072

Expression profiles

Bgee: expression breadth ubiquitous, 225 present calls, max score 95.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.1151 / max 278.9210, expressed in 1034 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
31595	2.8861	826
31597	1.2706	618
31596	0.4419	272
31592	0.3465	126
31593	0.0932	29
31590	0.0365	6
31594	0.0244	4
31591	0.0160	3

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	95.19	gold quality
dorsal root ganglion	UBERON:0000044	89.74	gold quality
endothelial cell	CL:0000115	86.38	gold quality
trigeminal ganglion	UBERON:0001675	85.63	gold quality
myocardium	UBERON:0002349	85.60	silver quality
parietal pleura	UBERON:0002400	83.84	gold quality
lateral nuclear group of thalamus	UBERON:0002736	83.66	gold quality
secondary oocyte	CL:0000655	83.55	gold quality
germinal epithelium of ovary	UBERON:0001304	83.28	gold quality
Brodmann (1909) area 23	UBERON:0013554	82.32	gold quality
tibial nerve	UBERON:0001323	80.88	gold quality
pericardium	UBERON:0002407	80.81	gold quality
cardiac muscle of right atrium	UBERON:0003379	80.73	silver quality
heart right ventricle	UBERON:0002080	80.55	gold quality
saphenous vein	UBERON:0007318	80.44	gold quality
skin of hip	UBERON:0001554	80.19	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.16	gold quality
visceral pleura	UBERON:0002401	79.25	gold quality
middle temporal gyrus	UBERON:0002771	78.69	gold quality
Brodmann (1909) area 46	UBERON:0006483	78.35	gold quality
dorsal plus ventral thalamus	UBERON:0001897	77.71	gold quality
lateral globus pallidus	UBERON:0002476	77.55	gold quality
descending thoracic aorta	UBERON:0002345	77.30	gold quality
occipital lobe	UBERON:0002021	76.89	gold quality
primary visual cortex	UBERON:0002436	76.32	gold quality
ventral tegmental area	UBERON:0002691	76.28	gold quality
popliteal artery	UBERON:0002250	76.00	gold quality
tibial artery	UBERON:0007610	75.97	gold quality
coronary artery	UBERON:0001621	75.94	gold quality
aorta	UBERON:0000947	75.77	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-6	yes	159.77
E-CURD-119	yes	11.12
E-ANND-3	yes	6.92

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

259 targeting FIGN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548AW	99.99	72.57	3559
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787

Literature-anchored findings (GeneRIF, showing 5)

• The loss of Fidgetin induces a microtubule-dependent enlargement of mitotic centrosomes and an increase in the number and length of astral microtubules. (PMID:22672901)
• FIGN +94762G>C polymorphism reduced the risk of congenital heart defects by activating the transcription of an alternative FIGN isoform, inhibiting proteasome activity and allowing the accumulation of RFC1 and DHFR, promoting folate transmembrane transport and utilization. (PMID:28302752)
• FIGN might play an important role in decreased congenital heart defect risk by upregulating plasma folate concentration during embryo heart development (PMID:28534241)
• Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma. (PMID:33162817)
• Comprehensive characterization of Fidgetin on tumor immune microenvironment evaluation and immunotherapy in human hepatocellular carcinoma. (PMID:38421251)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	fign	ENSDARG00000008662
mus_musculus	Fign	ENSMUSG00000075324
rattus_norvegicus	Fign	ENSRNOG00000004679
drosophila_melanogaster	Fign	FBGN0031519
drosophila_melanogaster	kat-60L1	FBGN0037375
drosophila_melanogaster	Kat60	FBGN0040208
caenorhabditis_elegans	mei-1	WBGENE00003183
caenorhabditis_elegans		WBGENE00017981

Paralogs (9): SPAST (ENSG00000021574), KATNAL1 (ENSG00000102781), VPS4B (ENSG00000119541), FIGNL1 (ENSG00000132436), VPS4A (ENSG00000132612), ATAD1 (ENSG00000138138), KATNAL2 (ENSG00000167216), KATNA1 (ENSG00000186625), FIGNL2 (ENSG00000261308)

Protein

Protein identifiers

Fidgetin — Q5HY92 (reviewed: Q5HY92)

All UniProt accessions (2): Q5HY92, B8ZZS6

UniProt curated annotations — full annotation on UniProt →

Function. ATP-dependent microtubule severing protein. Severs microtubules along their length and depolymerizes their ends, primarily the minus-end, that may lead to the suppression of microtubule growth from and attachment to centrosomes. Microtubule severing may promote rapid reorganization of cellular microtubule arrays and the release of microtubules from the centrosome following nucleation. Microtubule release from the mitotic spindle poles may allow depolymerization of the microtubule end proximal to the spindle pole, leading to poleward microtubule flux and poleward motion of chromosome.

Subunit / interactions. Interacts with AKAP8 (via C-terminus).

Subcellular location. Nucleus matrix. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome.

Similarity. Belongs to the AAA ATPase family.

RefSeq proteins (2): NP_001308754, NP_060556* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003593	AAA+_ATPase	Domain
IPR003959	ATPase_AAA_core	Domain
IPR003960	ATPase_AAA_CS	Conserved_site
IPR015415	Spast_Vps4_C	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR047828	Fidgetin_ATPase	Domain
IPR050304	MT-severing_AAA_ATPase	Family

Pfam: PF00004, PF09336

UniProt features (16 total): region of interest 4, sequence variant 3, compositionally biased region 3, binding site 2, chain 1, modified residue 1, mutagenesis site 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5HY92-F1	62.06	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 489; 529–534

Post-translational modifications (1): 400

Mutagenesis-validated functional residues (1):

Position	Phenotype
532	inhibits the ability to sever and depolymerize microtubules.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 245 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOZGIT_ESR1_TARGETS_DN, LHX3_01, CHX10_01, GOCC_MICROTUBULE_ORGANIZING_CENTER, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, NKX62_Q2, DAWSON_METHYLATED_IN_LYMPHOMA_TCL1, chr2q24, GTGTTGA_MIR505, IRF1_Q6, GOCC_CENTROSOME, ATTACAT_MIR3803P

GO Biological Process (2): microtubule severing (GO:0051013), cell division (GO:0051301)

GO Molecular Function (5): ATP binding (GO:0005524), microtubule severing ATPase activity (GO:0008568), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), centrosome (GO:0005813), microtubule (GO:0005874), nuclear matrix (GO:0016363), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
microtubule cytoskeleton organization	2
ATP-dependent activity	2
cellular anatomical structure	2
cellular process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
polypeptide conformation or assembly isomerase activity	1
catalytic activity, acting on a protein	1
microtubule destabilizing activity	1
ribonucleoside triphosphate phosphatase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
nuclear lumen	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1734 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FIGN	KATNB1	Q9BVA0	635
FIGN	CPNE4	Q96A23	474
FIGN	GRB14	Q14449	436
FIGN	KCNH7	Q9NS40	423
FIGN	STPG2	Q8N412	402
FIGN	ZNF197	O14709	396
FIGN	TCERG1	O14776	395
FIGN	OR4B1	Q8NGF8	390
FIGN	ATL2	Q8NHH9	369
FIGN	STAC2	Q6ZMT1	368
FIGN	FAM199X	Q6PEV8	368
FIGN	CHMP1B	Q7LBR1	365
FIGN	KATNBL1	Q9H079	354
FIGN	MEI1	Q5TIA1	354
FIGN	ATL3	Q6DD88	352

IntAct

12 interactions, top by confidence:

A	B	Type	Score
FIGN	CHERP	psi-mi:“MI:0915”(physical association)	0.560
HGS	FIGN	psi-mi:“MI:0915”(physical association)	0.560
ERP44	MEX3A	psi-mi:“MI:0914”(association)	0.530
COPS5	FBLL1	psi-mi:“MI:0914”(association)	0.350
LANCL1	MYO7A	psi-mi:“MI:0914”(association)	0.350
PAX9	BCL9	psi-mi:“MI:2364”(proximity)	0.270
CHERP	FIGN	psi-mi:“MI:0915”(physical association)	0.000
HGS	FIGN	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): FIGN (Affinity Capture-MS), FIGN (Affinity Capture-MS), FIGN (Affinity Capture-MS), FIGN (Affinity Capture-RNA), FIGN (Two-hybrid), HGS (Two-hybrid), FIGN (Affinity Capture-MS), FIGN (Affinity Capture-RNA), FIGN (Affinity Capture-MS), FIGN (Proximity Label-MS), FIGN (Proximity Label-MS), FIGN (Proximity Label-MS), FIGN (Proximity Label-MS), FIGN (Affinity Capture-MS)

ESM2 similar proteins: A0JMA9, A2VDN5, A4IHT0, A8XV40, B2GUY1, B3DL84, B3M301, B3P8A3, B4HGG6, B4K799, B4M0H8, B4QSF0, B7PXE3, F4IRW0, F4JEX5, F4JY37, O13839, O16299, O43078, Q05AS3, Q3B8D5, Q503S1, Q53WJ1, Q5HY92, Q64702, Q6AZT2, Q6DDU8, Q6DJS0, Q6GX84, Q6NW58, Q6PAD2, Q6PIW4, Q6PL18, Q700C2, Q719N1, Q7ZXG4, Q8BPY9, Q8CDM1, Q8I0P1, Q8IYT4

Diamond homologs: A0A8I6AGW3, A0LR74, A2VDN5, A4IHT0, A6NMB9, B2RYN7, B3M301, B3P8A3, B4F6J6, B4G437, B4HGG6, B4JII0, B4K799, B4M0H8, B4NBP4, B4PL32, B4QSF0, B7PXE3, D0FH76, D2VS83, E9QEA3, F4JEX5, F6QV99, J3QK54, O05209, O14114, O14325, O15381, O16299, O28972, O57940, O60058, P03974, P23787, P25694, P32794, P36966, P40340, P46462, P54609

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

102 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	97
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1702 predictions. Top by Δscore:

Variant	Effect	Δscore
2:163612431:T:C	donor_gain	1.0000
2:163735832:TCTTA:T	donor_loss	1.0000
2:163735833:CTTAC:C	donor_loss	1.0000
2:163735834:TTA:T	donor_loss	1.0000
2:163735835:TACCT:T	donor_loss	1.0000
2:163735836:ACC:A	donor_loss	1.0000
2:163735837:C:CT	donor_loss	1.0000
2:163611802:CAAGC:C	acceptor_gain	0.9900
2:163611805:GC:G	acceptor_gain	0.9900
2:163611805:GCC:G	acceptor_loss	0.9900
2:163611806:CC:C	acceptor_gain	0.9900
2:163611807:C:CC	acceptor_gain	0.9900
2:163611807:CT:C	acceptor_loss	0.9900
2:163611808:T:G	acceptor_loss	0.9900
2:163612374:C:CA	donor_gain	0.9900
2:163612404:G:C	donor_gain	0.9900
2:163612413:T:TA	donor_gain	0.9900
2:163612428:T:A	donor_gain	0.9900
2:163612446:G:GT	donor_gain	0.9900
2:163612464:T:TA	donor_gain	0.9900
2:163639505:C:CT	donor_gain	0.9900
2:163702449:A:AC	donor_gain	0.9900
2:163702453:C:CT	donor_gain	0.9900
2:163735836:A:AC	donor_gain	0.9900
2:163735837:C:CC	donor_gain	0.9900
2:163609736:T:TA	donor_gain	0.9800
2:163611804:AGC:A	acceptor_gain	0.9800
2:163611813:A:AC	acceptor_gain	0.9800
2:163611814:T:C	acceptor_gain	0.9800
2:163611815:T:C	acceptor_gain	0.9800

AlphaMissense

4939 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:163611618:C:G	A72P	1.000
2:163611629:A:G	L68P	1.000
2:163611632:A:G	L67P	1.000
2:163611656:A:T	I59K	1.000
2:163611609:A:C	Y75D	0.999
2:163611621:A:C	Y71D	0.999
2:163611625:T:A	K69N	0.999
2:163611625:T:G	K69N	0.999
2:163611626:T:A	K69I	0.999
2:163611638:G:A	S65F	0.999
2:163611639:A:G	S65P	0.999
2:163611641:G:T	A64E	0.999
2:163611642:C:G	A64P	0.999
2:163611647:A:G	L62P	0.999
2:163611653:G:A	S60F	0.999
2:163611656:A:C	I59R	0.999
2:163611656:A:G	I59T	0.999
2:163611662:T:A	D57V	0.999
2:163611672:A:G	W54R	0.999
2:163611672:A:T	W54R	0.999
2:163609581:A:G	W751R	0.998
2:163609581:A:T	W751R	0.998
2:163610878:C:A	R318S	0.998
2:163610878:C:G	R318S	0.998
2:163610879:C:A	R318M	0.998
2:163610879:C:G	R318T	0.998
2:163611629:A:T	L68Q	0.998
2:163611638:G:T	S65Y	0.998
2:163611644:G:A	T63I	0.998
2:163611647:A:T	L62Q	0.998

dbSNP variants (sampled 300 via entrez): RS1000004693 (2:163617614 T>C), RS1000050880 (2:163629868 T>C), RS1000084401 (2:163621670 C>A,T), RS1000111852 (2:163623184 T>A,C), RS1000117704 (2:163631171 T>A), RS1000122656 (2:163718027 A>G), RS1000161405 (2:163673694 G>A), RS1000169855 (2:163608309 A>G), RS1000186546 (2:163628833 C>A,G,T), RS1000189531 (2:163721807 TAGTAA>T), RS1000235526 (2:163629156 G>A,T), RS1000280009 (2:163726801 T>G), RS1000288906 (2:163682588 G>C,T), RS1000382713 (2:163661317 G>A), RS1000384603 (2:163689591 G>A)

Disease associations

OMIM: gene MIM:605295 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

61 associations (top):

Study	Trait	p-value
GCST000462_1	Response to antipsychotic treatment	3.000000e-06
GCST000483_9	Folate pathway vitamin levels	8.000000e-08
GCST001072_4	Blood pressure	4.000000e-11
GCST001235_8	Blood pressure	2.000000e-08
GCST001236_9	Blood pressure	6.000000e-12
GCST002497_7	Blood pressure	2.000000e-06
GCST002783_382	Body mass index	5.000000e-08
GCST002783_539	Body mass index	9.000000e-07
GCST002833_1	Platinum-induced myelosuppression in non-small cell lung cancer	7.000000e-06
GCST002875_157	Diisocyanate-induced asthma	1.000000e-06
GCST003272_8	Systolic blood pressure	3.000000e-08
GCST003275_6	Mean arterial pressure	2.000000e-06
GCST003374_1	Chronic kidney disease	6.000000e-06
GCST004279_4	Systolic blood pressure	1.000000e-11
GCST004495_41	BMI (adjusted for smoking behaviour)	2.000000e-06
GCST004497_89	Body mass index (joint analysis main effects and smoking interaction)	2.000000e-06
GCST004499_36	BMI in non-smokers	7.000000e-06
GCST004745_3	Immunoglobulin A vasculitis	6.000000e-06
GCST004775_17	Pulse pressure	3.000000e-11
GCST004776_12	Systolic blood pressure	3.000000e-13
GCST004777_48	Diastolic blood pressure	2.000000e-11
GCST005979_8	Systolic blood pressure	3.000000e-11
GCST006010_22	Mean arterial pressure	1.000000e-09
GCST006021_18	Systolic blood pressure	6.000000e-07
GCST006187_7	Diastolic blood pressure (cigarette smoking interaction)	2.000000e-23
GCST006188_21	Systolic blood pressure (cigarette smoking interaction)	1.000000e-34
GCST006258_47	Diastolic blood pressure	2.000000e-12
GCST006259_30	Systolic blood pressure	2.000000e-14
GCST007045_18	PR interval	2.000000e-11
GCST007095_123	Systolic blood pressure	4.000000e-12

EFO canonical traits (18, from GWAS)

EFO ID	Trait name
EFO:0004729	vitamin measurement
EFO:0006335	systolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0006340	mean arterial pressure
EFO:0004340	body mass index
EFO:0007053	myelosuppression
EFO:0006995	response to diisocyanate
EFO:0004318	smoking behavior
EFO:1000965	Henoch-Schoenlein purpura
EFO:0006336	diastolic blood pressure
EFO:0006527	smoking status measurement
EFO:0004462	PR interval
EFO:0008579	risk-taking behaviour
EFO:0008039	BMI-adjusted hip circumference
EFO:0007828	daytime rest measurement
EFO:0009749	age at first sexual intercourse measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, increases expression	3
Cyclosporine	decreases expression, increases expression	3
Acetaminophen	decreases expression	2
Nickel	decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
Cadmium Chloride	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases methylation	1
terbufos	increases methylation	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione	decreases expression	1
potassium chromate(VI)	decreases expression	1
pentanal	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	affects expression, increases reaction	1
Vorinostat	increases expression	1
Panobinostat	increases reaction, affects expression	1
Arsenic	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	affects cotreatment, decreases expression	1
Fonofos	increases methylation	1
Estradiol	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.